Clinical Trials Browser

Phase 1/2 × pirfenidone × 90 days × Clear all

NCT04467723 2026-01-28

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Recurrence